Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Elicera Therapeutics AB (ELIC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.95 +0.01    +1.50%
30/04 - Closed. Currency in SEK ( Disclaimer )
  • Volume: 10,446
  • Bid/Ask: 0.94 / 0.94
  • Day's Range: 0.93 - 0.95
Type:  Equity
Market:  Sweden
ISIN:  SE0015382080 
S/N:  35093268
Elicera Therapeutics AB 0.95 +0.01 +1.50%

Elicera Therapeutics AB Company Profile

 
Get an in-depth profile of Elicera Therapeutics AB, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

2

Equity Type

ORD

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/II clinical trial for neuroendocrine tumors indications; ELC-201 for the treatment of various injectable solid tumors; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy for the treatment of solid tumors. Elicera Therapeutics AB (publ) has collaboration with the Josep Carreras Leukemia Research Institute to provide iTANK platform. The company was incorporated in 2014 and is based in Gothenburg, Sweden.

Contact Information

Address World Trade Centre Gothenburg Floor 7
Mässans gata 10 Gothenburg, 412 51
Sweden
Phone 46 7 03 31 90 51
Fax -

Top Executives

Name Age Since Title
Agneta Edberg 66 2020 Independent Chairman
Jan Zetterberg 71 2020 Independent Director
Christina Herder 61 2020 Independent Director
Margareth Jorvid 61 2020 Independent Director
Magnus Essand 59 2014 Chief Science Officer, Co-Founder & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ELIC Comments

Write your thoughts about Elicera Therapeutics AB
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email